AR and male reproductive organ cancer: Moreover, as recently reviewed by Casanova-Salas et al., CTCs genetic profiling holds strong predictive potential for the identification of responders among prostate patients that receive androgen receptor signaling inhibitors (ARSI), PARP inhibitors and other therapeutic regimes [22].